TY - JOUR
T1 - Patient-oriented perspective on chemokine receptor expression and function in glioma
AU - Isci, Damla
AU - D’uonnolo, Giulia
AU - Wantz, May
AU - Rogister, Bernard
AU - Lombard, Arnaud
AU - Chevigné, Andy
AU - Szpakowska, Martyna
AU - Neirinckx, Virginie
N1 - Funding Information:
This work was supported by the University of Li?ge, and the Fonds L?on Fr?d?ricq Association, Luxembourg Institute of Health (LIH), Luxembourg National Research Fund (INTER/FNRS grants 20/15084569, and PRIDE 11012546 ?NextImmune? and 14254520 ?I2TRON?), F.R.S.-FNRS-T?l?vie (grants 7.4593.19, 7.4529.19 and 7.8504.20). MS and AC are part of the Marie Sk?odowska-Curie Innovative Training Networks ONCORNET2.0 ?ONCOgenic Receptor Network of Excellence and Training? (MSCA-ITN-2020-ETN).
Funding Information:
Funding: This work was supported by the University of Liège, and the Fonds Léon Frédéricq Association, Luxembourg Institute of Health (LIH), Luxembourg National Research Fund (INTER/FNRS grants 20/15084569, and PRIDE 11012546 “NextImmune” and 14254520 “I2TRON”), F.R.S.-FNRS-Télévie (grants 7.4593.19, 7.4529.19 and 7.8504.20). MS and AC are part of the Marie Skłodowska-Curie Innovative Training Networks ONCORNET2.0 “ONCOgenic Receptor Network of Excellence and Training” (MSCA-ITN-2020-ETN).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Gliomas are severe brain malignancies, with glioblastoma (GBM) being the most aggressive one. Despite continuous efforts for improvement of existing therapies, overall survival remains poor. Over the last years, the implication of chemokines and their receptors in GBM development and progression has become more evident. Recently, large amounts of clinical data have been made available, prompting us to investigate chemokine receptors in GBM from a still-unexplored patient-oriented perspective. This study aims to highlight and discuss the involvement of chemokine receptors—CCR1, CCR5, CCR6, CCR10, CX3CR1, CXCR2, CXCR4, ACKR1, ACKR2, and ACKR3—most abundantly expressed in glioma patients based on the analysis of publicly available clinical datasets. Given the strong intratumoral heterogeneity characterizing gliomas and especially GBM, receptor expression was investigated by glioma molecular groups, by brain region distribution, emphasizing tissue-specific receptor functions, and by cell type enrichment. Our study constitutes a clinically relevant and patient-oriented guide that recapitulates the expression profile and the complex roles of chemokine receptors within the highly diversified glioma landscape. Additionally, it strengthens the importance of patient-derived material for development and precise amelioration of chemokine receptor-targeting therapies.
AB - Gliomas are severe brain malignancies, with glioblastoma (GBM) being the most aggressive one. Despite continuous efforts for improvement of existing therapies, overall survival remains poor. Over the last years, the implication of chemokines and their receptors in GBM development and progression has become more evident. Recently, large amounts of clinical data have been made available, prompting us to investigate chemokine receptors in GBM from a still-unexplored patient-oriented perspective. This study aims to highlight and discuss the involvement of chemokine receptors—CCR1, CCR5, CCR6, CCR10, CX3CR1, CXCR2, CXCR4, ACKR1, ACKR2, and ACKR3—most abundantly expressed in glioma patients based on the analysis of publicly available clinical datasets. Given the strong intratumoral heterogeneity characterizing gliomas and especially GBM, receptor expression was investigated by glioma molecular groups, by brain region distribution, emphasizing tissue-specific receptor functions, and by cell type enrichment. Our study constitutes a clinically relevant and patient-oriented guide that recapitulates the expression profile and the complex roles of chemokine receptors within the highly diversified glioma landscape. Additionally, it strengthens the importance of patient-derived material for development and precise amelioration of chemokine receptor-targeting therapies.
KW - Chemokine receptor
KW - Glioma
KW - Malignant processes
KW - Patient-derived transcriptomic data
KW - Tumor microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85121705883&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/35008294
U2 - 10.3390/cancers14010130
DO - 10.3390/cancers14010130
M3 - Review article
C2 - 35008294
AN - SCOPUS:85121705883
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 1
M1 - 130
ER -